Stock Ratings / Health Care / XRAY / financials

LMAT (74) KMTS (43) INSP (61) ATEC (38) ⌘ Pro Terminal →

DENTSPLY SIRONA Inc. (XRAY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$9.61 +1.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.62

DENTSPLY SIRONA Inc. (XRAY) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.92B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.62 (+0.13%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 6.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XRAY)Realized 20D OHLCV Swing Band: ±7.8%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY XRAY SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (30% of score)

20D Institutional Volume Accumulation (±7.8% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 55.1 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk5/20 pts (-15 pt drag)

Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.83-2.9% Next Q

Q2 (-2Q)

Grade D$8.57+10% Next Q

Q3 (-1Q)

Grade D$9.43+1.9% Next Q

Current

Grade D$9.61-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XRAY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XRAY currently carries a cautious 46/100 (D) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.70) and Max Pain ($10.09) forces dealer call-delta covering toward $15.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XRAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XRAY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How XRAY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$235.0M (6.4% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $3.96B

FY24

Rev $3.79B

FY25

Rev $3.68B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$3.68B	50%	-11.5%	-$598.0M	$235.0M	-11%
FY 2024	$3.79B	51.6%	-23.2%	-$910.0M	$461.0M	-21.3%
FY 2023	$3.96B	50%	-2.1%	-$132.0M	$377.0M	-11%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XRAY)

✓Walkthrough of XRAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XRAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.21%📐 HORIZONTAL RANGE

2026-10-30O $9.55H $9.68L $9.41C $9.61VOL 3.50M

RES: $11.64SUP: $8.20SMA50: $9.70SMA200: $11.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XRAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XRAY Butterfly Map → + Track XRAY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XRAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XRAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XRAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XRAY)

Health Care Rank #441 of 1016 ⚔️ LMAT vs XRAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XRAY vs. LMAT, KMTS, INSP, ATEC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DENTSPLY SIRONA Inc. (XRAY) ranks #441 by composite RQD confidence (46/100, grade D) and #269 by equity capitalization ($1.92B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with XRAY at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XRAY ACTIVE DENTSPLY SIRONA Inc.	D	46/100	—	50.0%	-11.0%	+1.80%	$1.92B	Benchmark Subject
LMAT LeMaitre Vascular Inc.	B	74/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	/lmat-vs-xray →
KMTS Kestra Medical Technologies Ltd.	D-	43/100	—	51.4%	-35.0%	+2.48%	$1.82B	/kmts-vs-xray →
INSP Inspire Medical Systems Inc.	C-	61/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	/insp-vs-xray →
ATEC Alphatec Holdings Inc.	D-	38/100	—	69.6%	-18.4%	-0.70%	$1.76B	/atec-vs-xray →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818479

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DENTSPLY SIRONA Inc. (XRAY) reported GAAP revenue of $3.68B (-3.0% vs. FY2024 revenue of $3.79B , and -7.2% cumulative change since FY2023) , GAAP net income of -$598.0M, operating cash flow of $235.0M, and free cash flow of $235.0M (-49.0% YoY). On the balance sheet, XRAY closed FY2025 with $5.43B in total assets against $2.02B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.68B	-$598.0M	$235.0M	$235.0M	$5.43B	$2.02B
FY2024 (FY)	2024-12-31	$3.79B	-$910.0M	$461.0M	$461.0M	$5.75B	$1.59B
FY2023 (FY)	2023-12-31	$3.96B	-$132.0M	$377.0M	$377.0M	—	—

3. XRAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XRAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $9.61 (+1.80% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XRAY ranks #441 in composite RQD confidence.

How does XRAY compare to LMAT and KMTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XRAY carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 50.0%, and ROIC of -11.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a B grade (74/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and KMTS (Kestra Medical Technologies Ltd.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.82B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XRAY?

Per XRAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818479), DENTSPLY SIRONA Inc. generated $3.68B in revenue (-3.0% YoY), -$598.0M in net income, and $235.0M in free cash flow against $5.43B in total assets and $2.02B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XRAY trading relative to its 50-day, 200-day, and 52-week technical levels?

XRAY last traded at $9.61 (+1.80% on volume of 3,552,540 shares), positioning the stock -0.93% below its 50-day simple moving average ($9.70) and -15.18% below its 200-day simple moving average ($11.33). Across its 52-week range of $8.32 to $14.76, XRAY sits at the 20.0% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.8% ($8.86 to $10.36).

XRAY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is DENTSPLY SIRONA Inc. (XRAY)?

In FY 2025 (10-K), XRAY converted $3.7B of revenue into a 50% gross margin, 0% operating margin, and $235.0M in free cash flow (6.4% FCF margin).

Direct Sub-Reports: XRAY RQD Cockpit XRAY 12M Forecast XRAY Earnings & Move XRAY Dividends & DRIP XRAY Insiders & 13F XRAY Whale Options XRAY Profit Sankey XRAY News & Why